Please login to the form below

FDA awards grant for cancer drug study

The US FDA has awarded a $1.6m grant under its orphan drugs programme to a Alabama-based biotech company Egen to help the company with clinical trials of a potential new therapy for ovarian cancer

The US Food and Drug Administration (FDA) has awarded a $1.6m grant under its orphan drugs programme to a small, Alabama-based biotech company called Egen to help the company with clinical trials of a potential new therapy for ovarian cancer.

The four-year grant is intended to assist in the phase II clinical development of the privately held company's lead product, Egen-001, which is being developed for the treatment of advanced recurrent ovarian cancer.

The drug is an interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 enhances the body's immune system against cancer and inhibits tumour blood supply, according to Egen.

The product has completed two phase I trials: one as monotherapy in platinum-resistant ovarian cancer patients, and the other in combination with carboplatin/docetaxel chemotherapy in platinum-sensitive ovarian cancer patients.

The FDA granted orphan drug status to Egen-001 in 2005. The status, which is reserved for drugs intended to treat diseases that affect fewer than 200,000 Americans, carries a number of benefits, including seven years of US marketing exclusivity, tax breaks and eligibility for help with clinical trial costs.

This is Egen's second grant for the drug from the FDA. The first, totaling $1m, was awarded in 2005.

3rd February 2011

PME Digital Edition

Featured jobs

Principal Health Economist - North-West: Negotiable

Medical Writer: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager- Healthcare Advertising: Negotiable

Account Director: Competitive Salary Offered

Associate Director: £75, 000-90, 000

Account Executive/ Senior Account Executive: competitive Salary Offfered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Healthcare Communications Account Directors x 2: Salary TBC

Senior Editorial Assistant – Greater Manchester: DOE

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Associate Medical Director: Excellent PTO, bonus and 401k package

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Account Manager / Account Director: Competative

Account Director – Healthcare Marketing – Berks: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Business Development Director – Health Education: excellent commission

Senior Account Manager: Competitive Salary Offered

Account Manager / Senior Account Manager: 35, 000-40, 000

Business Director: Competitive Salary Offered

Medical (Scientific) Director: £120, 000 benefits

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Systematic Reviewer - Oxford: Negotiable

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...